GLUE
GLUE
US61225M1027
Monte Rosa Therapeutics, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue 123.672.000 75.622.000
63.5%
Cost of Revenue -- --
--
Gross Profit -- --
--
177.880.000 156.734.000
13.5%
Operating Income -54.208.000 -81.112.000
33.2%
Pretax Income -39.723.000 -70.130.000
43.4%
Net Income Common Stockholders -38.626.000 -72.700.000
46.9%
-- --
--
-- --
--
ende